etidronate has been researched along with Neoplasms in 37 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Etidronate, when administered intravenously at 30 mg/kg during a period of 24 hours, apparently was safe and effective in this study for treatment of hypercalcemia in patients with a wide variety of tumor types." | 9.07 | Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy. ( Belani, CP; Chang, AY; Chapman, RA; Flores, JF; Hoff, JV; Pritchard, JD; Rude, RK, 1994) |
| "This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate disodium (EHDP) in the treatment of cancer-related hypercalcemia." | 9.07 | Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. ( Gucalp, R; Keller, A; Mallette, LE; Neidhart, J; Richman, SP; Ritch, P; Sarma, PR; Siegel, R; Tauer, K; Wiernik, PH, 1992) |
| "A dose-ranging, baseline-controlled study was undertaken to assess the safety and effectiveness of a 24-hour infusion of etidronate disodium in treating patients with hypercalcemia of malignant disease." | 9.07 | Effectiveness of a 24-hour infusion of etidronate disodium in the treatment of hypercalcemia of malignant disease. A dose-ranging pilot study. ( Flores, JF; Rude, RK; Singer, FR, 1991) |
| "In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days." | 9.07 | Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. ( Lad, TE; Recker, RR; Ringenberg, QS; Ritch, PS; Ryzen, E; Schiller, JH; Singer, FR, 1991) |
| "Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia (serum calcium level, greater than 11." | 9.06 | Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. ( Benson, AB; Bockman, RS; Citrin, DL; Greco, FA; Harvey, HA; Rasmussen, P; Schiller, JH; Siris, ES; Stock, JL; Witte, RS, 1987) |
| " While the exact mechanism of action remains poorly understood, etidronate, the only bisphosphonate currently available in the United States for the treatment of hypercalcemia, decreases the elevated serum calcium levels and alleviates the symptoms associated with hypercalcemia of malignancy." | 8.78 | Role of the bisphosphonate etidronate in the therapy of cancer-related hypercalcemia. ( Singer, FR, 1990) |
| "Etidronate was administered as a 4-hour IV infusion at a dose of 7." | 6.67 | A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. ( Heller, G; Murphy, WK; O'Dwyer, PJ; Schulman, P; Warrell, RP, 1991) |
| "Hypercalcemia of malignancy is a commonly encountered serious clinical problem that often requires aggressive therapy." | 5.28 | Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. ( Fatemi, S; Rude, RK; Singer, FR, 1992) |
| "Etidronate, when administered intravenously at 30 mg/kg during a period of 24 hours, apparently was safe and effective in this study for treatment of hypercalcemia in patients with a wide variety of tumor types." | 5.07 | Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy. ( Belani, CP; Chang, AY; Chapman, RA; Flores, JF; Hoff, JV; Pritchard, JD; Rude, RK, 1994) |
| "This multicenter, double-blind, randomized trial was performed to determine the efficacy and safety of pamidronate disodium (APD) in comparison to etidronate disodium (EHDP) in the treatment of cancer-related hypercalcemia." | 5.07 | Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. ( Gucalp, R; Keller, A; Mallette, LE; Neidhart, J; Richman, SP; Ritch, P; Sarma, PR; Siegel, R; Tauer, K; Wiernik, PH, 1992) |
| "A dose-ranging, baseline-controlled study was undertaken to assess the safety and effectiveness of a 24-hour infusion of etidronate disodium in treating patients with hypercalcemia of malignant disease." | 5.07 | Effectiveness of a 24-hour infusion of etidronate disodium in the treatment of hypercalcemia of malignant disease. A dose-ranging pilot study. ( Flores, JF; Rude, RK; Singer, FR, 1991) |
| "In a prospective, randomized, double-blind, multicenter study, 202 patients with cancer from 19 medical centers were treated for hypercalcemia of malignancy with daily intravenous infusions of etidronate disodium (136 patients) or saline alone (66 patients) for 3 consecutive days." | 5.07 | Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. ( Lad, TE; Recker, RR; Ringenberg, QS; Ritch, PS; Ryzen, E; Schiller, JH; Singer, FR, 1991) |
| "Normocalcemic patients with cancer who had been successfully treated for an episode of hypercalcemia were enrolled in a randomized, multisite, double-blind, placebo-controlled trial designed to determine the efficacy of maintenance oral etidronate in preventing the recurrence of moderate to severe hypercalcemia (serum calcium level, greater than 11." | 5.06 | Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. ( Benson, AB; Bockman, RS; Citrin, DL; Greco, FA; Harvey, HA; Rasmussen, P; Schiller, JH; Siris, ES; Stock, JL; Witte, RS, 1987) |
| "As part of a multicenter trial of etidronate disodium for control of hypercalcemia in patients with malignancies, patients achieving normocalcemia within seven days after starting intravenous therapy with etidronate disodium plus saline were enrolled into a double-blind, placebo-controlled trial of oral etidronate disodium to maintain normocalcemia." | 5.06 | Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients. ( Ringenberg, QS; Ritch, PS, 1987) |
| "We have found 11 cases of BRONJ in our hospital: 4 women taking oral alendronate or risendronate for osteoporosis and 7 cancer patients treated with intravenous zolendronic acid." | 4.88 | [Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces]. ( Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A, 2012) |
| "Recent information on the pathophysiology and treatment of hypercalcemia of malignancy is reviewed, and the roles of two new agents, gallium nitrate and pamidronate, are discussed." | 4.78 | Update on the medical treatment of hypercalcemia of malignancy. ( Hall, TG; Schaiff, RA, 1993) |
| " While the exact mechanism of action remains poorly understood, etidronate, the only bisphosphonate currently available in the United States for the treatment of hypercalcemia, decreases the elevated serum calcium levels and alleviates the symptoms associated with hypercalcemia of malignancy." | 4.78 | Role of the bisphosphonate etidronate in the therapy of cancer-related hypercalcemia. ( Singer, FR, 1990) |
| "Two diphosphonates, EHDP (disodium etidronate, or ethane-hydroxy-diphosphonate) and Cl2MDP (disodium clodronate, or dichloromethylene-diphosphonate) were injected in various doses in 8 patients who had had one or more episodes of malignant hypercalcemia." | 3.66 | [Treatment of hypercalcemia of tumoral origin with two diphosphonates]. ( Chantraine, A; Courvoisier, B; Jung, A; van Ouwenaller, C, 1980) |
| "Etidronate was administered as a 4-hour IV infusion at a dose of 7." | 2.67 | A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. ( Heller, G; Murphy, WK; O'Dwyer, PJ; Schulman, P; Warrell, RP, 1991) |
| "Indomethacin was effective in only one of five patients to whom it was given, and EHDP was effective also in only one of five patients." | 2.65 | Comparative study of available medical therapy for hypercalcemia of malignancy. ( Heath, DA; Mundy, GR; Wilkinson, R, 1983) |
| "Skeletal metastases are often complicated by pain." | 2.44 | Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. ( de Klerk, JM; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2007) |
| "Hypercalcemia of malignancy (HCM) is a potentially life-threatening complication of cancer resulting from increased bone resorption by osteoclasts." | 2.41 | Treatment of hypercalcemia of malignancy with bisphosphonates. ( Berenson, JR, 2002) |
| "Specific treatment of cancer remains essential to prevent TIH relapse." | 2.41 | [Tumor-induced hypercalcemia. Review of bisphosphonate treatment]. ( Lortholary, A, 2001) |
| " Mineralisation defects in forming bone may be avoided by the use of an initial dosage of 5 mg/kg/day for up to 6 months; dosages above 10 mg/kg/day should be limited to 3 months' duration, and dosages greater than 20 mg/kg/day should be avoided." | 2.39 | Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. ( Dunn, CJ; Fitton, A; Sorkin, EM, 1994) |
| "Haematologic malignancies and solid tumors are often complicated by the bone tissue destruction." | 2.39 | [Pharmacologic therapy of bone tissue changes due to hematologic malignancies and bone metastasis]. ( Kiełbiński, M, 1994) |
| "Treatment of cancer associated hypercalcaemia is based on an initial phase of volume repletion with isotonic saline, followed by drug treatment to inhibit bone resorption." | 2.39 | Pathogenesis and management of cancer associated hypercalcaemia. ( Ralston, SH, 1994) |
| "Hypercalcemia of malignancy is a commonly encountered serious clinical problem that often requires aggressive therapy." | 1.28 | Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. ( Fatemi, S; Rude, RK; Singer, FR, 1992) |
| " The author discusses the administration, dosage and side effects, and results of current studies." | 1.28 | Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy. ( Coleman, RE, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (29.73) | 18.7374 |
| 1990's | 18 (48.65) | 18.2507 |
| 2000's | 4 (10.81) | 29.6817 |
| 2010's | 4 (10.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Roix, JJ | 1 |
| Harrison, SD | 1 |
| Rainbolt, EA | 1 |
| Meshaw, KR | 1 |
| McMurry, AS | 1 |
| Cheung, P | 1 |
| Saha, S | 1 |
| Cheng, A | 1 |
| Chen, S | 1 |
| Zhang, Y | 1 |
| Yin, D | 1 |
| Dong, M | 1 |
| Vestergaard, P | 1 |
| Schwartz, K | 1 |
| Rejnmark, L | 1 |
| Mosekilde, L | 2 |
| Pinholt, EM | 1 |
| Arranz Caso, JA | 1 |
| Flores Ballester, E | 1 |
| Ngo Pombe, S | 1 |
| López Pizarro, V | 1 |
| Dominguez-Mompello, JL | 1 |
| Restoy Lozano, A | 1 |
| Berenson, JR | 1 |
| Lam, MG | 1 |
| de Klerk, JM | 1 |
| van Rijk, PP | 1 |
| Zonnenberg, BA | 1 |
| Mundy, GR | 2 |
| Wilkinson, R | 1 |
| Heath, DA | 1 |
| Jung, A | 2 |
| van Ouwenaller, C | 1 |
| Chantraine, A | 1 |
| Courvoisier, B | 2 |
| Dunn, CJ | 1 |
| Fitton, A | 1 |
| Sorkin, EM | 1 |
| Kiełbiński, M | 1 |
| Flores, JF | 2 |
| Rude, RK | 3 |
| Chapman, RA | 1 |
| Belani, CP | 1 |
| Chang, AY | 1 |
| Pritchard, JD | 1 |
| Hoff, JV | 1 |
| Hall, TG | 1 |
| Schaiff, RA | 1 |
| Kinirons, MT | 1 |
| Ralston, SH | 3 |
| Lortholary, A | 1 |
| Das, H | 1 |
| Wang, L | 1 |
| Kamath, A | 1 |
| Bukowski, JF | 1 |
| Barras, C | 1 |
| Mermillod, B | 1 |
| Fatemi, S | 1 |
| Singer, FR | 4 |
| Gucalp, R | 1 |
| Ritch, P | 1 |
| Wiernik, PH | 1 |
| Sarma, PR | 1 |
| Keller, A | 1 |
| Richman, SP | 1 |
| Tauer, K | 1 |
| Neidhart, J | 1 |
| Mallette, LE | 1 |
| Siegel, R | 1 |
| Coleman, RE | 1 |
| List, A | 1 |
| Ritch, PS | 2 |
| Lad, TE | 1 |
| Ringenberg, QS | 2 |
| Schiller, JH | 2 |
| Recker, RR | 1 |
| Ryzen, E | 2 |
| Horowitz, E | 1 |
| Miller, JL | 1 |
| Rose, LI | 1 |
| Warrell, RP | 2 |
| Murphy, WK | 1 |
| Schulman, P | 1 |
| O'Dwyer, PJ | 1 |
| Heller, G | 1 |
| Gallacher, SJ | 2 |
| Parel, U | 1 |
| Boyle, IT | 2 |
| Patel, U | 1 |
| Dryburgh, FJ | 1 |
| Fraser, WD | 1 |
| Cowan, RA | 1 |
| Hasling, C | 1 |
| Charles, P | 1 |
| Kanis, JA | 1 |
| Urwin, GH | 1 |
| Gray, RE | 1 |
| Beneton, MN | 1 |
| McCloskey, EV | 1 |
| Hamdy, NA | 1 |
| Murray, SA | 1 |
| Rasmussen, P | 1 |
| Benson, AB | 1 |
| Witte, RS | 1 |
| Bockman, RS | 1 |
| Harvey, HA | 1 |
| Siris, ES | 1 |
| Citrin, DL | 1 |
| Greco, FA | 1 |
| Stock, JL | 1 |
| Martodam, RR | 1 |
| Troxell, M | 1 |
| Benson, A | 1 |
| Paterson, A | 1 |
| Shepard, K | 1 |
| Hicks, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 reviews available for etidronate and Neoplasms
| Article | Year |
|---|---|
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces].
Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphon | 2012 |
Treatment of hypercalcemia of malignancy with bisphosphonates.
Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; H | 2002 |
Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases.
Topics: Bone Neoplasms; Clinical Trials as Topic; Etidronic Acid; Humans; Medical Oncology; Models, Chemical | 2007 |
Etidronic acid. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Topics: Bone Diseases; Bone Remodeling; Bone Resorption; Clinical Trials as Topic; Drug Administration Sched | 1994 |
[Pharmacologic therapy of bone tissue changes due to hematologic malignancies and bone metastasis].
Topics: Bone Neoplasms; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Neoplasms; Osteo | 1994 |
Update on the medical treatment of hypercalcemia of malignancy.
Topics: Animals; Antineoplastic Agents; Calcitonin; Diphosphonates; Etidronic Acid; Gallium; Humans; Hyperca | 1993 |
Newer agents for the treatment of malignant hypercalcemia.
Topics: Diphosphonates; Etidronic Acid; Gallium; Humans; Hypercalcemia; Neoplasms; Pamidronate | 1993 |
Pathogenesis and management of cancer associated hypercalcaemia.
Topics: Antineoplastic Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Diuretics; Etidronic Aci | 1994 |
Bisphosphonates as cancer drugs.
Topics: Antineoplastic Agents; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Neoplasm Proteins; Ne | 1999 |
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].
Topics: Diagnosis, Differential; Diagnostic Errors; Diphosphonates; Etidronic Acid; Fluid Therapy; Hematolog | 2001 |
Etidronate for hypercalcemia of malignancy and osteoporosis.
Topics: Etidronic Acid; Humans; Hypercalcemia; Neoplasms; Ossification, Heterotopic; Osteitis Deformans; Ost | 1991 |
Role of the bisphosphonate etidronate in the therapy of cancer-related hypercalcemia.
Topics: Animals; Etidronic Acid; Humans; Hypercalcemia; Molecular Structure; Neoplasms | 1990 |
13 trials available for etidronate and Neoplasms
| Article | Year |
|---|---|
The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases.
Topics: Blood Cell Count; Bone Neoplasms; Electrocardiography; Etidronic Acid; Female; Follow-Up Studies; Hu | 2011 |
Comparative study of available medical therapy for hypercalcemia of malignancy.
Topics: Administration, Oral; Adult; Aged; Calcium; Clinical Trials as Topic; Diphosphonates; Etidronic Acid | 1983 |
Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy.
Topics: Adult; Aged; Calcium; Etidronic Acid; Female; Humans; Hypercalcemia; Infusions, Parenteral; Male; Mi | 1994 |
Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia.
Topics: Adult; Aged; Analysis of Variance; Calcium; Diphosphonates; Double-Blind Method; Etidronic Acid; Fem | 1992 |
Effectiveness of a 24-hour infusion of etidronate disodium in the treatment of hypercalcemia of malignant disease. A dose-ranging pilot study.
Topics: Etidronic Acid; Humans; Hypercalcemia; Infusions, Intravenous; Neoplasms; Pilot Projects; Time Facto | 1991 |
Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group.
Topics: Double-Blind Method; Etidronic Acid; Female; Fluid Therapy; Humans; Hypercalcemia; Infusions, Intrav | 1991 |
A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia.
Topics: Adult; Aged; Analysis of Variance; Calcium; Creatinine; Double-Blind Method; Etidronic Acid; Female; | 1991 |
Clinical trials of gallium nitrate in patients with cancer-related hypercalcemia.
Topics: Antineoplastic Agents; Calcitonin; Clinical Trials as Topic; Double-Blind Method; Drug Administratio | 1991 |
Study in 25 patients shows gallium nitrate superior therapy for hypercalcemia in cancer patients.
Topics: Antineoplastic Agents; Calcium; Etidronic Acid; Gallium; Humans; Hypercalcemia; Neoplasms | 1990 |
Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia.
Topics: Administration, Oral; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Drug Administration | 1989 |
Etidronate disodium for treating hypercalcaemia of malignancy: a double blind, placebo-controlled study.
Topics: Adult; Aged; Calcium; Clinical Trials as Topic; Double-Blind Method; Etidronic Acid; Female; Furosem | 1986 |
Maintenance etidronate in the prevention of malignancy-associated hypercalcemia.
Topics: Administration, Oral; Clinical Trials as Topic; Double-Blind Method; Etidronic Acid; Female; Humans; | 1987 |
Efficacy of oral administration of etidronate disodium in maintaining normal serum calcium levels in previously hypercalcemic cancer patients.
Topics: Administration, Oral; Calcium; Clinical Trials as Topic; Double-Blind Method; Etidronic Acid; Humans | 1987 |
12 other studies available for etidronate and Neoplasms
| Article | Year |
|---|---|
Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Dacarbazine; D | 2014 |
Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.
Topics: Administration, Oral; Aged; Alcoholism; Alendronate; Bisphosphonate-Associated Osteonecrosis of the | 2012 |
[Treatment of hypercalcemia of tumoral origin with two diphosphonates].
Topics: Adult; Aged; Bone Resorption; Bronchial Neoplasms; Diphosphonates; Esophageal Neoplasms; Etidronic A | 1980 |
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
Topics: Alendronate; Antigens; Cell Line, Transformed; Cytotoxicity, Immunologic; Diphosphonates; Etidronic | 2001 |
[Effect of 2 phosphonates on the osteolysis induced by tumor extracts].
Topics: Animals; Animals, Newborn; Clodronic Acid; Diphosphonates; Etidronic Acid; Mice; Neoplasm Metastasis | 1979 |
Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy.
Topics: Animals; Calcitonin; Calcium; Drug Therapy, Combination; Etidronic Acid; Humans; Hypercalcemia; Inje | 1992 |
Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
Topics: Animals; Bone and Bones; Bone Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hyp | 1991 |
Malignant hypercalcemia. The choice of therapy.
Topics: Etidronic Acid; Fluid Therapy; Humans; Hypercalcemia; Neoplasms | 1991 |
Hypercalcaemia in malignancy.
Topics: Diphosphonates; Etidronic Acid; Fluid Therapy; Humans; Hypercalcemia; Neoplasms | 1989 |
Etidronate disodium: a new therapy for hypercalcemia of malignancy. Proceedings of a symposium.
Topics: Etidronic Acid; Humans; Hypercalcemia; Neoplasms; Paraneoplastic Endocrine Syndromes | 1987 |
Effects of intravenous etidronate disodium on skeletal and calcium metabolism.
Topics: Aged; Bone and Bones; Bone Diseases, Metabolic; Calcium; Etidronic Acid; Female; Humans; Hydroxyprol | 1987 |
Intravenous etidronate in the management of malignant hypercalcemia.
Topics: Adult; Aged; Breast Neoplasms; Calcium; Carcinoma, Squamous Cell; Etidronic Acid; Female; Head and N | 1985 |